Test Price
2,800 AEDโ Home Collection Available
๐ Results in 3โ4 weeks
RYR1 Gene Sequencing for King-Denborough Syndrome
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection โ Available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The RYR1 Gene Sequencing test for King-Denborough syndrome uses Next-Generation Sequencing (NGS) to detect pathogenic variants in the RYR1 gene, which are linked to congenital myopathy and malignant hyperthermia susceptibility. This genetic analysis is essential for confirming diagnosis, guiding anaesthesia safety, and enabling family screening.
| Feature | Our RYR1 NGS Test | Closest Alternative (Targeted Genotyping) |
|---|---|---|
| Methodology | Comprehensive NGS covering all exons and splice junctions (depth >150ร) | Limited hotspot analysis by Sanger sequencing; misses rare variants |
| Turnaround Time | 3โ4 weeks with detailed clinical interpretation | 4โ6 weeks without complete variant classification |
| Diagnostic Yield | High โ detects SNVs, indels, and copy number changes | Lower โ may miss structural variants and novel mutations |
Physician Insight & Safety Protocols
โAs a consultant medical geneticist deeply involved in hereditary muscle disorders, I want you to know that seeking clarity for muscle weakness and anaesthetic risks is a brave step. This test gives a molecular answer, but its true value emerges when combined with your clinical picture and family history. Please rememberโwe are here to support you at every stage, from counselling to interpretation.โ
Medication Advisory
Do not discontinue any prescribed medication or anaesthetic agents without consulting your doctor. This genetic test does not replace urgent clinical evaluation.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not a substitute for immediate medical care. It must be ordered by a qualified physician after thorough clinical assessment.
- PreโExisting Risk: Patients with a known personal or family history of malignant hyperthermia should strictly avoid triggering anaesthetics regardless of test outcome.
- Emergency Red Flags: If you experience sudden severe muscle rigidity, high fever, dark urine, or rapid heart rate, call 998 (UAE Ambulance) immediatelyโthese may indicate malignant hyperthermia crisis.
Patient FAQ & Clinical Guidance
1. What does the RYR1 gene detect?
It detects mutations in the RYR1 gene associated with King-Denborough syndrome and malignant hyperthermia susceptibility. This test uses comprehensive NGS to identify pathogenic variants, enabling accurate diagnosis and informed anaesthetic planning.
2. How is the sample collected?
A certified phlebotomist collects a small blood sample (peripheral whole blood) during a VIP home visit. Alternatively, a buccal swab or DNA card may be used if preferred. The collection is performed under strict cold-chain protocols to ensure sample integrity.
3. How long does it take to get results?
Results are typically delivered within 3 to 4 weeks. This turnaround includes advanced NGS sequencing, thorough variant curation, and a detailed clinical interpretation report prepared by the medical genetics team.
4. Can this test predict malignant hyperthermia risk?
Yes. Pathogenic variants in RYR1 are strongly associated with malignant hyperthermia susceptibility. A positive result indicates high risk; however, all patients with relevant personal or family history should follow strict anaesthetic precautions regardless of the test result.
5. Is pre-test genetic counselling required?
Pre-test genetic counselling is strongly recommended. A consultant medical geneticist will construct a detailed pedigree, discuss implications, and obtain informed consent. This ensures that the test is appropriate and that you fully understand the results.
UAE Regulatory & Data Privacy Adherence
- Data Protection: Compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Patient Consent: All genetic testing follows Federal Decree-Law No. 4 of 2016 on Medical Liability for clinical safety and informed consent.
- Accreditation: ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). All procedures adhere to DHA standards and international best practices.
Clinical & Logistical Metadata
| Test Name | RYR1 Gene Sequencing for King-Denborough Syndrome |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Peripheral whole blood (preferred) or buccal swab |
| Methodology Used | Next-Generation Sequencing (NGS) โ full gene coverage including all exons and splice junctions |
| ICD-10-CM Code | G71.2 |
| LOINC Code | 82283-4 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
Preparation Required
["No specific fasting required", "Do not discontinue prescribed medication without consulting a doctor"]
Medically Reviewed by Dr. Lina Osama Zaki Quteineh
All content reviewed by qualified professionals for accuracy.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians